First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer.
作者信息
Besbes S, Billard C
机构信息
1] INSERM U965, Hôpital Lariboisière, Paris, France [2] Université Paris Diderot-Paris 7, Paris, France.
出版信息
Cell Death Dis. 2015 Jul 9;6(7):e1810. doi: 10.1038/cddis.2015.168.
Abstract
摘要
相似文献
1
First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer.
Cell Death Dis. 2015 Jul 9;6(7):e1810. doi: 10.1038/cddis.2015.168.
2
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Cell Death Dis. 2015 Jan 15;6(1):e1590. doi: 10.1038/cddis.2014.561.
3
The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Crit Rev Oncol Hematol. 2016 Apr;100:32-6. doi: 10.1016/j.critrevonc.2016.02.003. Epub 2016 Feb 11.
4
It's time to die: BH3 mimetics in solid tumors.
Biochim Biophys Acta Mol Cell Res. 2021 Apr;1868(5):118987. doi: 10.1016/j.bbamcr.2021.118987. Epub 2021 Feb 15.
5
Seeking a MCL-1 inhibitor.
Cell Death Differ. 2013 Nov;20(11):1440-1. doi: 10.1038/cdd.2013.114.
6
Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Int Rev Cell Mol Biol. 2020;351:23-55. doi: 10.1016/bs.ircmb.2020.01.002. Epub 2020 Feb 5.
7
Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
BMC Res Notes. 2018 Mar 27;11(1):197. doi: 10.1186/s13104-018-3302-0.
8
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in -Mutant Non-Small Cell Lung Cancer.
Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.
9
Evaluation and critical assessment of putative MCL-1 inhibitors.
Cell Death Differ. 2013 Nov;20(11):1475-84. doi: 10.1038/cdd.2013.79. Epub 2013 Jul 5.
10
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Mol Pharmacol. 2019 Oct;96(4):419-429. doi: 10.1124/mol.119.116855.
引用本文的文献
1
Canonical and Noncanonical Functions of the BH3 Domain Protein Bid in Apoptosis, Oncogenesis, Cancer Therapeutics, and Aging.
Cancers (Basel). 2024 Jun 12;16(12):2199. doi: 10.3390/cancers16122199.
2
Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2.
ChemMedChem. 2020 Sep 16;15(18):1691-1698. doi: 10.1002/cmdc.202000278. Epub 2020 Jun 25.
3
BCL-2 family isoforms in apoptosis and cancer.
Cell Death Dis. 2019 Feb 21;10(3):177. doi: 10.1038/s41419-019-1407-6.
4
Prediction of Hot Spots at Myeloid Cell Leukemia-1-Inhibitor Interface Using Energy Estimation and Alanine Scanning Mutagenesis.
Biochemistry. 2018 Feb 20;57(7):1249-1261. doi: 10.1021/acs.biochem.7b01048. Epub 2018 Feb 1.
5
Chalepin: A Compound from L. Pers Exhibits Cell Cycle Arrest at S phase, Suppresses Nuclear Factor-Kappa B (NF-κB) Pathway, Signal Transducer and Activation of Transcription 3 (STAT3) Phosphorylation and Extrinsic Apoptotic Pathway in Non-small Cell Lung Cancer Carcinoma (A549).
Pharmacogn Mag. 2017 Oct;13(Suppl 3):S489-S498. doi: 10.4103/pm.pm_13_17. Epub 2017 Oct 11.
6
RNA Polymerase Tags To Monitor Multidimensional Protein-Protein Interactions Reveal Pharmacological Engagement of Bcl-2 Proteins.
J Am Chem Soc. 2017 Aug 30;139(34):11964-11972. doi: 10.1021/jacs.7b06152. Epub 2017 Aug 15.
7
Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.
Oncotarget. 2017 Jul 18;8(29):46801-46817. doi: 10.18632/oncotarget.8695.
8
Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.
Oncotarget. 2016 Apr 5;7(14):18965-77. doi: 10.18632/oncotarget.7879.
本文引用的文献
1
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Cell Death Dis. 2015 Jan 15;6(1):e1590. doi: 10.1038/cddis.2014.561.
2
Small molecule Mcl-1 inhibitors for the treatment of cancer.
Pharmacol Ther. 2015 Jan;145:76-84. doi: 10.1016/j.pharmthera.2014.08.003. Epub 2014 Aug 27.
3
Targeting BCL2 for the treatment of lymphoid malignancies.
Semin Hematol. 2014 Jul;51(3):219-27. doi: 10.1053/j.seminhematol.2014.05.008. Epub 2014 May 15.
4
BH3 mimetics: status of the field and new developments.
Mol Cancer Ther. 2013 Sep;12(9):1691-700. doi: 10.1158/1535-7163.MCT-13-0058. Epub 2013 Aug 23.
5
Delving deeper: MCL-1's contributions to normal and cancer biology.
Trends Cell Biol. 2013 Jan;23(1):22-9. doi: 10.1016/j.tcb.2012.08.011. Epub 2012 Sep 28.
6
The essential role of evasion from cell death in cancer.
Adv Cancer Res. 2011;111:39-96. doi: 10.1016/B978-0-12-385524-4.00002-7.
Zotero 插件